American biotechnology company Moderna expects that the course of her vaccine against COVID-19 will cost $50-60. This is with reference to its sources said the publication of the Financial Times.
This price will be valid in the United States and countries with high levels of income, said the newspaper.
The representative of Moderna said that negotiations with governments on the supply of the drug, has received a preliminary title mRNA-1273, but the issue price is called confidential.
The Financial Times notes that pharmaceutical companies Pfizer and BioNTech in negotiations with the American government assumed the cost of adding two doses of their vaccines will not exceed $39.
In mid-July, Moderna announced the successful completion of the second phase of clinical trials. It was attended by 45 people, aged 18 to 55 years. July 27, started the third and final phase of testing the mRNA-1273, it was attended by 30 thousand volunteers.
According to who, currently about 160 test vaccine against the coronavirus SARS-CoV-2 worldwide.